Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3

Frontiers in Microbiology

Volumn 4, Issue NOV, 2013, Pages

  Senchi, Kyosuke ^a   Matsunaga, Satoko ^a   Hasegawa, Hideki ^b   Kimura, Hirokazu ^b   Ryo, Akihide ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Adjuvant; HN; HPIV3; Oligomannose coated liposome; Vaccine

Indexed keywords

ADJUVANT; DOUBLE STRANDED RNA; HN PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOSOME; MANNOSE OLIGOSACCHARIDE; MESSENGER RNA; PARAINFLUENZA VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; IN VITRO STUDY; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS INFECTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; VACCINATION;

EID: 84890307437     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2013.00346     Document Type: Article

References (43)

1. Ainai, A., Ichinohe, T., Tamura, S., Kurata, T., Sata, T., Tashiro, M., et al. (2010). Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J. Med. Virol. 82, 476-484. doi: 10.1002/jmv.21694.
2. Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and innate immunity. Cell 124, 783-801. doi: 10.1016/j.cell.2006.02.015.
3. Ambrose, M. W., Wyde, P. R., Ewasyshyn, M., Bonneau, A. M., Caplan, B., Meyer, H. L., et al. (1991). Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats. Vaccine 9, 505-511. doi: 10.1016/0264-410X(91)90037-7.
4. Belshe, R. B., Newman, F. K., Anderson, E. L., Wright, P. F., Karron, R. A., Tollefson, S., et al. (2004). Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. 190, 2096-2103. doi: 10.1086/425981.
5. Brideau, R. J., Oien, N. L., Lehman, D. J., Homa, F. L., and Wathen, M. W. (1993). Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein. J. Gen. Virol. 74, 471-477. doi: 10.1099/0022-1317-74-3-471.
6. Counihan, M. E., Shay, D. K., Holman, R. C., Lowther, S. A., and Anderson, L. J. (2001). Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr. Infect. Dis. J. 20, 646-653. doi: 10.1097/00006454-200107000-00003.
7. de Haan, A., Geerligs, H. J., Huchshorn, J. P., Van Scharrenburg, G. J., Palache, A. M., and Wilschut, J. (1995). Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13, 155-162. doi: 10.1016/0264-410X(95)93129-W.
8. Durrer, P., Gluck, U., Spyr, C., Lang, A. B., Zurbriggen, R., Herzog, C., et al. (2003). Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21, 4328-4334. doi: 10.1016/S0264-410X(03)00457-2.
9. Endo, Y., and Sawasaki, T. (2006). Cell-free expression systems for eukaryotic protein production. Curr. Opin. Biotechnol 17, 373-380. doi: 10.1016/j.copbio.2006.06.009.
10. Fukasawa, M., Shimizu, Y., Shikata, K., Nakata, M., Sakakibara, R., Yamamoto, N., et al. (1998). Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett. 441, 353-356. doi: 10.1016/S0014-5793(98)01577-4.
11. Giddam, A. K., Zaman, M., Skwarczynski, M., and Toth, I. (2012). Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine (Lond.) 7, 1877-1893. doi: 10.2217/nnm.12.157.
12. Glezen, W. P., Frank, A. L., Taber, L. H., and Kasel, J. A. (1984). Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J. Infect. Dis. 150, 851-857. doi: 10.1093/infdis/150.6.851.
13. Haller, A. A., Miller, T., Mitiku, M., and Coelingh, K. (2000). Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J. Virol. 74, 11626-11635. doi: 10.1128/JVI.74.24.11626-11635.2000.
14. Hasegawa, H., Ichinohe, T., Ainai, A., Tamura, S., and Kurata, T. (2009). Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther. Clin. Risk Manag. 5, 125-132. doi: 10.2147/TCRM.S3297.
15. Henrickson, K. J. (2003). Parainfluenza viruses. Clin. Microbiol. Rev. 16, 242-264. doi: 10.1128/CMR.16.2.242-264.2003.
16. Hirabayashi, Y., Kurata, H., Funato, H., Nagamine, T., Aizawa, C., Tamura, S., et al. (1990). Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8, 243-248. doi: 10.1016/0264-410X(90)90053-O.
17. Ichinohe, T., Watanabe, I., Ito, S., Fujii, H., Moriyama, M., Tamura, S., et al. (2005). Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79, 2910-2919. doi: 10.1128/JVI.79.5.2910-2919.2005.
18. Ishii, M., and Kojima, N. (2010). Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Glycoconj. J. 27, 115-123. doi: 10.1007/s10719-009-9263-8.
19. Kamphuis, T., Shafique, M., Meijerhof, T., Stegmann, T., Wilschut, J., and De Haan, A. (2013). Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine 31, 2169-2176. doi: 10.1016/j.vaccine.2013.02.043.
20. Karron, R. A., Belshe, R. B., Wright, P. F., Thumar, B., Burns, B., Newman, F., et al. (2003). A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J. 22, 394-405. doi: 10.1097/01.inf.0000066244.31769.83.
21. Karron, R. A., Casey, R., Thumar, B., Surman, S., Murphy, B. R., Collins, P. L., et al. (2011). The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children. Pediatr. Infect. Dis. J. 30, e186-e191. doi: 10.1097/INF.0b013e31822ea24f.
22. Karron, R. A., Thumar, B., Schappell, E., Surman, S., Murphy, B. R., Collins, P. L., et al. (2012). Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 30, 3975-3981. doi: 10.1016/j.vaccine.2011.12.022.
23. Mader, D., Huang, Y., Wang, C., Fraser, R., Issekutz, A. C., Stadnyk, A. W., et al. (2000). Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge. Vaccine 18, 1110-1117. doi: 10.1016/S0264-410X(99)00373-4.
24. Mason, J. N., Elbahesh, H., and Russell, C. J. (2013). Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines. J. Virol. 87, 5959-5969. doi: 10.1128/JVI.00227-13.
25. Mizuta, K., Saitoh, M., Kobayashi, M., Tsukagoshi, H., Aoki, Y., Ikeda, T., et al. (2011). Detailed genetic analysis of hemagglutinin-neuraminidase glycoprotein gene in human parainfluenza virus type 1 isolates from patients with acute respiratory infection between 2002 and 2009 in Yamagata prefecture, Japan. Virol. J. 8, 533. doi: 10.1186/1743-422X-8-533.
26. Morein, B., Sharp, M., Sundquist, B., and Simons, K. (1983). Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice. J. Gen. Virol. 64, 1557-1569. doi: 10.1099/0022-1317-64-7-1557.
27. Moscona, A. (2005). Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J. Clin. Invest. 115, 1688-1698. doi: 10.1172/JCI25669.
28. Mostov, K. E., and Deitcher, D. L. (1986). Polymeric immunoglobulin receptor expressed in MDCK cells transcytoses IgA. Cell 46, 613-621. doi: 10.1016/0092-8674(86)90887-1.
29. Nishimura, M., Kohara, J., Kuroda, Y., Hiasa, J., Tanaka, S., Muroi, Y., et al. (2013). Oligomannose-coated liposome-entrapped dense granule protein 7 induces protective immune response to Neospora caninum in cattle. Vaccine 31, 3528-3535. doi: 10.1016/j.vaccine.2013.05.083.
30. Nochi, T., and Kiyono, H. (2006). Innate immunity in the mucosal immune system. Curr. Pharm. Des 12, 4203-4213. doi: 10.2174/138161206778743457.
31. Porotto, M., Palmer, S. G., Palermo, L. M., and Moscona, A. (2012). Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry. J. Biol. Chem. 287, 778-793. doi: 10.1074/jbc.M111.298059.
32. Ray, R., Brown, V. E., and Compans, R. W. (1985). Glycoproteins of human parainfluenza virus type 3: characterization and evaluation as a subunit vaccine. J. Infect. Dis. 152, 1219-1230. doi: 10.1093/infdis/152.6.1219.
33. Ray, R., Glaze, B. J., Moldoveanu, Z., and Compans, R. W. (1988). Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3. J. Infect. Dis. 157, 648-654. doi: 10.1093/infdis/157.4.648.
34. Sato, S., and Kiyono, H. (2012). The mucosal immune system of the respiratory tract. Curr. Opin. Virol. 2, 225-232. doi: 10.1016/j.coviro.2012.03.009.
35. Schmidt, A. C. (2011). Progress in respiratory virus vaccine development. Semin. Respir. Crit. Care Med. 32, 527-540. doi: 10.1055/s-0031-1283289.
36. Schmidt, A. C., Mcauliffe, J. M., Murphy, B. R., and Collins, P. L. (2001). Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75, 4594-4603. doi: 10.1128/JVI.75.10.4594-4603.2001.
37. Schmidt, A. C., Schaap-Nutt, A., Bartlett, E. J., Schomacker, H., Boonyaratanakornkit, J., Karron, R. A., et al. (2011). Progress in the development of human parainfluenza virus vaccines. Expert. Rev. Respir. Med. 5, 515-526. doi: 10.1586/ers.11.32.
38. Shimizu, Y., Takagi, H., Nakayama, T., Yamakami, K., Tadakuma, T., Yokoyama, N., et al. (2007). Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages. Parasite Immunol. 29, 229-239. doi: 10.1111/j.1365-3024.2007.00937.x.
39. Skiadopoulos, M. H., Surman, S., Tatem, J. M., Paschalis, M., Wu, S. L., Udem, S. A., et al. (1999). Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73, 1374-1381.
40. Takai, K., Sawasaki, T., and Endo, Y. (2010). Practical cell-free protein synthesis system using purified wheat embryos. Nat Protoc. 5, 227-238. doi: 10.1038/nprot.2009.207.
41. Takeda, K., Kaisho, T., and Akira, S. (2003). Toll-like receptors. Annu. Rev. Immunol. 21, 335-376. doi: 10.1146/annurev.immunol.21.120601.141126.
42. Tamura, S., and Kurata, T. (2004). Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn. J. Infect. Dis. 57, 236-247.
43. Yuasa, T., Kawano, M., Tabata, N., Nishio, M., Kusagawa, S., Komada, H., et al. (1995). A cell fusion-inhibiting monoclonal antibody binds to the presumed stalk domain of the human parainfluenza type 2 virus hemagglutinin-neuraminidase protein. Virology 206, 1117-1125. doi: 10.1006/viro.1995.1035.